Alkermes ALKS Vivitrol — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Alkermes in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Alkermes’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alkermes's vivitrol — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alkermes's vivitrol — revenue?
- Alkermes (ALKS) reported vivitrol — revenue of $112.43M in Q1 2026.
- How has Alkermes's vivitrol — revenue changed year-over-year?
- Alkermes's vivitrol — revenue increased by 11.3% year-over-year, from $101M to $112.43M.
- What is the long-term trend for Alkermes's vivitrol — revenue?
- Over 4 years (2021 to 2025), Alkermes's vivitrol — revenue has grown at a 8.0% compound annual growth rate (CAGR), from $343.85M to $467.91M.
- What does vivitrol — revenue mean?
- The total net sales revenue generated by a specific product after accounting for all commercial adjustments.
- How do you interpret vivitrol — revenue?
- An increase indicates growing market demand, successful commercial execution, or effective pricing strategies, while a decrease may signal market saturation, increased competition, or loss of patent exclusivity.
- How does vivitrol — revenue compare across companies?
- Comparable to net product sales reported by other biotechnology and pharmaceutical firms for their key therapeutic assets.